Can TILs be associated with prognostic factors and survival rates in breast cancer? A retrospective analysis

Autores

  • Fernanda Martins Armond Faleiros Hospital Sírio-Libanês, Ensino e Pesquisa, Postgraduate Molecular Oncology – São Paulo (SP), Brazil. Faculdade Santa Casa de Belo Horizonte, Ensino e Pesquisa, Postgraduate – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0002-5226-4572
  • Francisco Chagas Lima e Silva Faculdade Santa Casa de Belo Horizonte, Ensino e Pesquisa, Postgraduate – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0002-6991-1465
  • Débora Balabram Universidade Federal de Minas Gerais, Faculdade de Medicina, Department of Surgery – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0003-3077-7526
  • Marcelo Araújo Buzelin Faculdade Santa Casa de Belo Horizonte, Ensino e Pesquisa, Postgraduate – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0002-8442-8797
  • Cristiana Buzelin Nunes Universidade Federal de Minas Gerais, Faculdade de Medicina, Pathological Anatomy and Forensic Medicine – Belo Horizonte (MG), Brazil. https://orcid.org/0000-0002-5266-6870

DOI:

https://doi.org/10.29289/2594539420230004

Palavras-chave:

survival analysis, breast cancer, immunohistochemistry, tumor-infiltrating lymphocytes, tumor biomarkers, prognostic factors

Resumo

Introduction: The relationship between the tumor inflammatory infiltrate, also known as tumor-infiltrating lymphocytes (TILs), and invasive breast carcinomas has been extensively studied in recent years to verify its association with prognosis and response to treatment. The goal of this study was to associate the presence of TILs with patient’s survival time. Methods: We studied prognostic clinicopathological characteristics already established in the literature and their impact on overall five-year survival time of patients with invasive breast cancer treated at Hospital Santa Casa in Belo Horizonte, Minas Gerais, Brazil, in 2011 (n=290). This was an observational and retrospective study. Results: The presence of TILs was associated with tumors of no special type (p=0.018) and with younger age of the patients (p=0.042). Smaller tumor size (HR: 19.24; 95%CI 4.30–86.15; p<0.001), absence of metastasis to the axillary lymph nodes (HR: 2.80; 95%CI 1.02–7.70; p=0.002), positivity for progesterone receptor (HR: 0.39; 95%CI 0.17–0.87; p=0.022), and presence of TILs (HR: 0.23; 95%CI 0.08–0.65; p=0.005) were associated with longer survival times. Conclusions: This study suggests that the presence of TILs, along with other clinicopathological characteristics, is a prognostic factor in breast cancer.

Downloads

Não há dados estatísticos.

Referências

1. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br. J. Cancer. 2005;93(9):1046-52. https://doi.org/10.1038/sj.bjc.6602787

2. Bleiweiss IJ. Pathology of breast cancer. UpToDate; 2016 [cited on 2019 Mar 15]. Available from: https://www.uptodate.com/contents/pathology-of-breast-cancer

3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492

4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660

5. Santos MO, Lima FCS, Martins LFL, Oliveira JFP, Almeida LM, Cancela MC. Estimativa de incidência de câncer no Brasil, 2023-2025. Rev Bras Cancerol. 2023;69(1):e-213700. https://doi.org/10.32635/2176-9745.RBC.2023v69n1.3700

6. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8. https://doi.org/10.1038/ni1102-991

7. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium, and escape. Curr Opin Immunol. 2014;27:16-25. https://doi.org/10.1016/j.coi.2014.01.004

8. Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L. Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open. 2017;2(%):e000255. https://doi.org/10.1136/esmoopen-2017-000255

9. Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49(2):141-55. https://doi.org/10.1016/j.pathol.2016.10.010

10. Matsumoto H, Thike AA, Li H, Yeong J, Koo SL, Dent RA, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156(2):237-47. https://doi.org/10.1007/s10549-016-3743-x

11. Mahmoud SMA, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AHS, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-55. https://doi.org/10.1200/jco.2010.30.5037

12. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354-60. https://doi.org/10.1001/jamaoncol.2016.1061

13. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer. 2016;4:59. https://doi.org/10.1186/s40425-016-0165-6

14. McDonald KA, Kawaguchi T, Qi Q, Peng X, Asaoka M, Young J, et al. Tumor heterogeneity correlates with less immune response and worse survival in breast cancer patients. Ann Surg Oncol. 2019;26(7):2191-9. https://doi.org/10.1245/s10434-019-07338-3

15. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(20):2105-22. https://doi.org/10.1200/JCO.2018.77.8738

16. Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38(12):1346-66. https://doi.org/10.1200/jco.19.02309

17. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. Chicago: AJCC; 2018

18. World Health Organization. Breast Tumours. WHO classification of tumours. Lyon: WHO; 2019.

19. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259-71. https://doi.org/10.1093/annonc/mdu450

20. Mohammed ZMA, Going JJ, Edwards J, Elsberger B, Doughty JC, McMillan DC. The relationship between components of tumour inflammatory cell infiltrate and clinicopathological factors and survival in patients with primary operable invasive ductal breast cancer. Br J Cancer. 2012;107(5):864-73. https://doi.org/10.1038/bjc.2012.347

21. Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the breast cancer microenvironment: detection, characterization, and clinical implication. Breast Cancer. 2017;24(1):3-15. https://doi.org/10.1007/s12282-016-0698-z

22. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. https://doi.org/10.1016/j.cell.2011.02.013

23. Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G, Orecchia R, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer. 2009;45(8):1381-8. https://doi.org/10.1016/j.ejca.2008.11.041

24. Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13(4):228-41. https://doi.org/10.1038/nrclinonc.2015.215

25. Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40-50. https://doi.org/10.1016/S1470-2045(17)30904-X

26. Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical validity and utility of tumor-infiltrating lymphocytes in routine clinical practice for breast cancer patients: current and future directions. Front Oncol. 2017;7:156. https://doi.org/10.3389/fonc.2017.00156

27. Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJC, van der Vlugt-Daane M, et al. Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun. 2016;7:12910. https://doi.org/10.1038/ncomms12910

28. Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14(3):R93. https://doi.org/10.1186/bcr3208

29. Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. Br J Cancer. 2017;117(4):451-60. https://doi.org/10.1038/bjc.2017.220

30. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050-9. https://doi.org/10.1038/nm1622

31. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690-714. https://doi.org/10.1016/j.ccell.2015.10.012

Downloads

Publicado

2026-03-13

Como Citar

Faleiros, F. M. A., Silva, F. C. L. e, Balabram, D., Buzelin, M. A., & Nunes, C. B. (2026). Can TILs be associated with prognostic factors and survival rates in breast cancer? A retrospective analysis. Mastology, 33. https://doi.org/10.29289/2594539420230004

Edição

v. 33 (2023)

Seção

Original Articles

Licença

Copyright (c) 2026 Fernanda Martins Armond Faleiros, Francisco Chagas Lima e Silva, Débora Balabram, Marcelo Araújo Buzelin, Cristiana Buzelin Nunes

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.